# Trial of Pimasertib in Hematological Malignancies

> **NCT00957580** · PHASE2 · TERMINATED · sponsor: **EMD Serono** · enrollment: 81 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute
- Hematologic Neoplasms

## Interventions

- **DRUG:** Pimasertib
- **DRUG:** Pimasertib
- **DRUG:** Pimasertib
- **DRUG:** Pimasertib
- **DRUG:** Pimasertib

## Key facts

- **NCT ID:** NCT00957580
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-09-30
- **Primary completion:** 2012-12-31
- **Final completion:** 2012-12-31
- **Target enrollment:** 81 (ACTUAL)
- **Why stopped:** The trial has been terminated due to an estimated low probability of clinical benefit based on limited anti-leukemic effects observed in safety run-in (Part 1)
- **Last updated:** 2017-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00957580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00957580, "Trial of Pimasertib in Hematological Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00957580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*